A Phase II Study of IGEV +/- Bortezomib Before Hign Dose Consolidation in Relapsed/Refractory Hodgkin's Lymphoma

NCT00636311 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

13

Enrollment

OTHER

Sponsor class

Conditions

Hodgkin Disease

Interventions

DRUG: Ifosfamide, Gemcitabine, Vinorelbine
DRUG: Bortezomib + IGEV

Sponsor

Istituto Clinico Humanitas